Neurohormonal regulation of cardiac ion channels in chronic heart failure

Junko Kurokawa1, Hugues Abriel

  • 1Department of Bio-Informational Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan.

Insights

Chronic heart failure involves harmful neurohormonal overactivation, affecting cardiac ion channels and increasing sudden death risk. This review explores how key hormones regulate these channels in heart failure pathophysiology.

Area of Science:

  • Cardiology
  • Neuroendocrinology
  • Molecular Biology

Background:

  • Chronic heart failure (CHF) is characterized by neurohormonal imbalance.
  • Overactivation of the renin-angiotensin-aldosterone system and sympathetic nervous system is prominent in CHF.
  • This hormonal dysregulation contributes to cardiac remodeling and ventricular arrhythmias, a major cause of mortality.

Purpose of the Study:

  • To review the regulation of cardiac ion channels by neurohormones central to CHF pathogenesis.
  • To elucidate the mechanisms linking hormonal pathways to arrhythmogenic remodeling in heart failure.

Main Methods:

  • Literature review focusing on neurohormonal regulation of cardiac ion channels in heart failure.
  • Analysis of studies investigating the role of the renin-angiotensin-aldosterone system and catecholamines.
  • Examination of the impact on ion channel function and cardiac electrophysiology.

Main Results:

  • Neurohormonal overactivation significantly alters cardiac ion channel function.
  • Dysregulation of ion channels contributes to arrhythmogenic remodeling and increased arrhythmia susceptibility.
  • All major drug classes reducing CHF mortality target these neurohormonal pathways.

Conclusions:

  • Understanding neurohormonal regulation of cardiac ion channels is crucial for managing CHF.
  • Targeting these pathways offers therapeutic strategies to prevent arrhythmias and reduce mortality in heart failure patients.
  • Further research into specific ion channel-hormone interactions may reveal novel treatment approaches.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Regulation of Heart Rates01:31

Regulation of Heart Rates

The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...